Risk of cancer induced by human papillomavirus in patients with immune-mediated inflammatory diseases: a nationwide matched cohort study.

IF 5.3 2区医学 Q1 RHEUMATOLOGY

RMD Open Pub Date : 2026-07-15 DOI:10.1136/rmdopen-2026-006927

Clothilde Gros, Tiphaine Goulenok, Jean-François Timsit, Karim Sacre, Arthur Mageau

{"title":"Risk of cancer induced by human papillomavirus in patients with immune-mediated inflammatory diseases: a nationwide matched cohort study.","authors":"Clothilde Gros, Tiphaine Goulenok, Jean-François Timsit, Karim Sacre, Arthur Mageau","doi":"10.1136/rmdopen-2026-006927","DOIUrl":null,"url":null,"abstract":"Introduction: Women with immune-mediated inflammatory diseases (IMIDs) are at an increased risk of human papillomavirus (HPV)-related cervical cancer. Our study aimed to assess the risk of HPV-induced cervical, vaginal, vulvar, anal and penile cancer in patients with IMIDs.Methods: We conducted a nationwide matched cohort study comparing patients with IMIDs with a control group using the French nationwide hospital medical information database between 2016 and 2023. The following IMIDs were considered: systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, mixed connective tissue disease and rheumatoid arthritis. The primary outcome was the occurrence of HPV-induced cancer or severe dysplasia.Results: A total of 122 316 patients with IMIDs and 316 047 matched controls were analysed over an 8-year study period, with a mean follow-up of 4.11 (2.47) years. IMIDs were associated with an increased risk of HPV-induced cancer or severe dysplasia (age-adjusted HR 1.99 (95% CI 1.80 to 2.20)) in all patients with IMIDs compared with matched controls. An increased risk was observed in patients with IMIDs for all types of HPV-induced cancer except penile cancer. In the multivariable competing risk analysis, the risk factors for HPV-induced cancer/severe dysplasia in the IMIDs population were female (HR: 5.88 (95% CI 4.01 to 8.61)), SLE (HR: 2.08 (95% CI 1.70 to 2.55)), age under 65 years (HR: 2.09 (95% CI 1.70 to 2.57)) and chronic kidney disease (HR: 1.44 (95% CI 1.18 to 1.77)).Conclusion: Patients with IMIDs are almost two times as likely to develop HPV-associated cancer or severe dysplasia, particularly at cervical, vulvar, vaginal and anal sites, compared with matched controls.","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"12 3","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13374448/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2026-006927","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Women with immune-mediated inflammatory diseases (IMIDs) are at an increased risk of human papillomavirus (HPV)-related cervical cancer. Our study aimed to assess the risk of HPV-induced cervical, vaginal, vulvar, anal and penile cancer in patients with IMIDs.

Methods: We conducted a nationwide matched cohort study comparing patients with IMIDs with a control group using the French nationwide hospital medical information database between 2016 and 2023. The following IMIDs were considered: systemic lupus erythematosus (SLE), Sjögren's syndrome, systemic sclerosis, mixed connective tissue disease and rheumatoid arthritis. The primary outcome was the occurrence of HPV-induced cancer or severe dysplasia.

Results: A total of 122 316 patients with IMIDs and 316 047 matched controls were analysed over an 8-year study period, with a mean follow-up of 4.11 (2.47) years. IMIDs were associated with an increased risk of HPV-induced cancer or severe dysplasia (age-adjusted HR 1.99 (95% CI 1.80 to 2.20)) in all patients with IMIDs compared with matched controls. An increased risk was observed in patients with IMIDs for all types of HPV-induced cancer except penile cancer. In the multivariable competing risk analysis, the risk factors for HPV-induced cancer/severe dysplasia in the IMIDs population were female (HR: 5.88 (95% CI 4.01 to 8.61)), SLE (HR: 2.08 (95% CI 1.70 to 2.55)), age under 65 years (HR: 2.09 (95% CI 1.70 to 2.57)) and chronic kidney disease (HR: 1.44 (95% CI 1.18 to 1.77)).

Conclusion: Patients with IMIDs are almost two times as likely to develop HPV-associated cancer or severe dysplasia, particularly at cervical, vulvar, vaginal and anal sites, compared with matched controls.

查看原文本刊更多论文

人乳头瘤病毒在免疫介导的炎症性疾病患者中诱发癌症的风险：一项全国性匹配队列研究

患有免疫介导炎症性疾病（IMIDs）的妇女患人乳头瘤病毒（HPV）相关宫颈癌的风险增加。本研究旨在评估IMIDs患者发生hpv诱导的宫颈、阴道、外阴、肛门和阴茎癌的风险。方法：我们使用法国全国医院医疗信息数据库，在2016年至2023年期间进行了一项全国范围内的匹配队列研究，将IMIDs患者与对照组进行比较。考虑以下IMIDs：系统性红斑狼疮（SLE）、Sjögren综合征、系统性硬化症、混合性结缔组织病和类风湿性关节炎。主要结局是hpv诱导的癌症或严重的不典型增生的发生。结果：在8年的研究期间，共分析了122216例IMIDs患者和31647例匹配对照，平均随访时间为4.11（2.47）年。与对照组相比，所有患有IMIDs的患者发生hpv诱导的癌症或严重发育不良的风险增加（经年龄调整的风险比1.99 (95% CI 1.80至2.20)）。除阴茎癌外，IMIDs患者患hpv诱导的所有类型癌症的风险均增加。在多变量竞争风险分析中，IMIDs人群中hpv诱导的癌症/严重不典型增生的危险因素为女性（HR: 5.88 (95% CI 4.01 ~ 8.61)）、SLE （HR: 2.08 (95% CI 1.70 ~ 2.55)）、年龄在65岁以下（HR: 2.09 (95% CI 1.70 ~ 2.57)）和慢性肾脏疾病（HR: 1.44 (95% CI 1.18 ~ 1.77)）。结论：与对照组相比，IMIDs患者发生hpv相关癌症或严重发育不良的可能性几乎是对照组的两倍，特别是在宫颈、外阴、阴道和肛门部位。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

RMD Open RHEUMATOLOGY-

CiteScore

7.30

自引率

6.50%

发文量

205

审稿时长

14 weeks

期刊介绍： RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.